SVASinovac Biotech, Ltd

CSNasdaq (XNAS)·USD

Identity

Enriched 2026-08-14 20:47

Market cap: —
Shares outstanding (class): 71,860,702
Shares outstanding (weighted): 71,860,702
SIC: —
Employees: 2,602
Location: —
Homepage: http://www.sinovac.com
Description: Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with unmet medical needs. It has developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus. The Company operates exclusively in the research, development, manufacture, and commercialization of vaccines sector. The Company's business is considered as operating in one segment. It has presence in Chinese Mainland, and Outside Chinese Mainland.

Market cap and share counts drift.

as of 2026-03-31

No reported positions at this date.

Positions are reached through OpenFIGI-resolved ISINs. A security with no resolved ISIN cannot be found this way even if funds do hold it.

master.security_identifier

TICKERSVA
CIK0001084201
ISINAGP8696W1045
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Not classified.

5,771 of 13,106 active securities have an assignment so far. This one is still in the queue.

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.